High ligand efficiency quinazoline compounds as novel A < sub > 2A < /sub > adenosine receptor antagonists

Eur J Med Chem. 2022 Jul 22;241:114620. doi: 10.1016/j.ejmech.2022.114620. Online ahead of print.ABSTRACTThe past fifty years have been marked by the surge of neurodegenerative diseases. Unfortunately, current treatments are only symptomatic. Hence, the search for new and innovative therapeutic targets for curative treatments becomes a major challenge. Among these targets, the adenosine A2A receptor (A2AAR) has been the subject of much research in recent years. In this paper, we report the design, synthesis and pharmacological analysis of quinazoline derivatives as A2AAR antagonists with high ligand efficiency. This class of molecules has been discovered by a virtual screening and bears no structural semblance with reference antagonist ZM-241385. More precisely, we identified a series of 2-aminoquinazoline as promising A2AAR antagonists. Among them, one compound showed a high affinity towards A2AAR (21a, Ki = 20 nM). We crystallized this ligand in complex with A2AAR, confirming one of our predicted docking poses and opening up possibilities for further optimization to derive selective ligands for specific adenosine receptor subtypes.PMID:35933788 | DOI:10.1016/j.ejmech.2022.114620
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research